BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20715163)

  • 1. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells.
    Abbasi M; Lavasanifar A; Berthiaume LG; Weinfeld M; Uludağ H
    Cancer; 2010 Dec; 116(23):5544-54. PubMed ID: 20715163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
    Dönmez Y; Gündüz U
    Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters).
    Yin Q; Shen J; Chen L; Zhang Z; Gu W; Li Y
    Biomaterials; 2012 Sep; 33(27):6495-506. PubMed ID: 22704597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles.
    Gao Y; Chen L; Zhang Z; Chen Y; Li Y
    Biomaterials; 2011 Feb; 32(6):1738-47. PubMed ID: 21112086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
    Abbasi M; Lavasanifar A; Uludag H
    Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA.
    Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z
    Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
    Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
    Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
    Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
    Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
    Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
    Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
    Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-mimetic polymeric micelles for targeted siRNA delivery.
    Xiong XB; Uludağ H; Lavasanifar A
    Biomaterials; 2010 Aug; 31(22):5886-93. PubMed ID: 20427082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
    Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
    Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
    Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
    Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.